Daptomycin in the treatment of infective endocarditis | CMAC

Daptomycin in the treatment of infective endocarditis

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(1):35-40

​ Popov D.A.
10.36488/cmac.2018.1.35-40
infective endocarditis daptomycin treatment
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(1):35-40

Abstract

This review characterizes daptomycin as a highly effective lipopeptide antibiotic being active against Gram-positive microorganisms, including multidrug resistant strains. The data reflecting the up-to-date daptomycin-based approaches to antimicrobial therapy of infective endocarditis which utilize this drug advantages over standard treatment regimens are presented. The data presented are illustrated with clinical cases.

Dmitriy A. Popov

A.N. Bakulev National Medical Research Center of Cardiovascular Surgery, Moscow, Russia

  • 1. Guleri A., Utili R., Dohmen P., Hamed K. Effectiveness and safety of daptomycin in patients with infective endocarditis undergoing heart valve replacement: a subgroup analysis from real-world data. Ther Adv Infect Dis. 2017;4(2):41-47.
  • 2. Fowler V.G., Jr., Miro J.M., Hoen B., et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005; 293:3012-3021.
  • 3. Habib G., Lancellotti P., Antunes M.J., et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2015;36(44):3075-3128.
  • 4. Baddour L.M., Wilson W.R., Bayer A.S., et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):14351486.
  • 5. Soriano A., Marco F., Martínez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193200.
  • 6. Gelfand B.R., Ed. Sepsis: classification, clinical and diagnostic conception and treatment. 4th revised and enlarged edition. Moscow, 2017. 408 p. Russian.
  • 7. Dvorchik B.H., Brazier D., DeBruin M.F., Arbeit R.D. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318-1323.
  • 8. Heinemann B., Kaplan M.A., Muir R.D., Hooper I.R. Amphomycin, a new antibiotic. Antibiot Chemother (Northfield). 1953;3:1239-1242.
  • 9. Eisenstein B.I., Oleson F.B., Baltz R.H. Daptomycin: From the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis. 2010;50(Suppl. 1):S10-S15.
  • 10. Dekhnich A.V., Danilov A.I. Daptomycin – the review of pharmacological, clinical and microbiological characteristics. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2010;12(4):295-313. Russian.
  • 11. Stefani S., Campanile F., Santagati M., et al. Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: a review of the available evidence. Int J Antimicrob Agents. 2015;46(3):278-289.
  • 12. Bals R., Wilson J.M. Cathelicidins – A family of multifunctional antimicrobial peptides. Cell Mol Life Sci. 2003;60:711-720.
  • 13. Scott W.R., Baek S.B., Jung D., Hancock R.E., Straus S.K. NMR structural studies of the antibiotic lipopeptide daptomycin in DHPC micelles. Biochim Biophys Acta. 2007;1768:3116-3126.
  • 14. Jung D., Rozek A., Okon M., Hancock R.E. Structural transitions as determinants of the action of the calciumdependent antibiotic daptomycin. Chem Biol. 2004;11:949-957.
  • 15. Epand R.F., Savage P.B., Epand R.M. Bacterial lipid composition and the antimicrobial efficacy of cationic steroid compounds (ceragenins). Biochim Biophys Acta. 2007;1768:2500-2509.
  • 16. Randall C.P., Mariner K.R., Chopra I., O’Neill A.J. The target of daptomycin is absent from Escherichia coli and other Gram-negative pathogens. Antimicrob Agents Chemother. 2013;57:637-639.
  • 17. Silverman J.A., Perlmutter N.G., Shapiro H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:2538-2544.
  • 18. Safdar N., Andes D., Craig W.A. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63-68.
  • 19. Oleson Jr. F.B., Berman C.L., Kirkpatrick J.B., et al. Oncedaily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000;44:2948-2953.
  • 20. Novartis Europharm, Ltd. Cubicin summary of product characteristics. London: European Medicines Agency; 2016.
  • 21. Fowler Jr. V.G., Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.
  • 22. Katz D.E., Lindfield K.C., Steenbergen J.N., et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008;62:1455-1464.
  • 23. Martone W.J., Lindfield K.C., Katz D.E. Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Pract. 2008;62:1183-1187.
  • 24. Falcone M., Russo A., Venditti M., Novelli A., Pai M.P. Considerations for higher doses of daptomycin in critically ill patients with methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57:1568-1576.
  • 25. Rose W.E., Leonard S.N., Sakoulas G., et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2008;52(3):831-836.
  • 26. Silverman J.A., Mortin L.I., Vanpraagh A.D., Li T., Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191(12):2149-2152.
  • 27. Dhand A., Bayer A.S., Pogliano J., et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53:158-163.
  • 28. Miro J.M., Entenza J.M., del Rio A., et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2012;56:4511-4515.
  • 29. Popov D.A., Zubareva N.A., Dekhnich A.V. Evidence based review on daptomycin use in the treatment of Gram-positive infections. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2016;18(4):270-281. Russian.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared